Navigation Links
Simbionix and Johnson & Johnson LLC Announce Distribution Agreement at Russia and the CIS Countries
Date:4/16/2009

CLEVELAND, Ohio, April 16 /PRNewswire/ -- Simbionix, the world's leading developer of medical simulation systems, today announced an agreement with Johnson & Johnson LLC for distribution of Simbionix's simulators and related products.

Johnson & Johnson, LLC operates in Russia, Ukraine and CIS countries and is one of the subsidiaries of Johnson & Johnson.

Johnson & Johnson LLC will have exclusive rights to distribute Simbionix's line of advanced medical simulators in hospitals in the Russia and CIS countries.

"We are very excited to enter into this collaboration with Johnson & Johnson LLC to bring our advanced simulators into the Russian republic' hospitals, teaching facilities and interventional clinics," said Simbionix CEO Gary Zamler. "This agreement ushers in a new era of simulation-based training for Russia's medical community and we envision beneficial for the countries covered by the agreement, Johnson & Johnson LLC,and Simbionix."

"In the last year, Simbionix has increased its distribution channels and its exposure to the international market, "explains Mr. Doron Zilberman, Simbionix's VP of International Sales. "We see Russia as one of the leading markets in the emerging medical world; this agreement is an additional step of our on going success in the international market ..."

About Simbionix

Simbionix is a global leader in medical simulation technology. Simbionix mission is to provide state of the art, computer-assisted metrics-based surgical simulation systems, and set the standard for minimally invasive surgical training and performance.

Simbionix products provide medical experts with hands-on training in a comprehensive array of MIS procedures, including; GI Endoscopy, Endourology, percutaneous access, advanced laparoscopic procedures and Endovascular procedures. Visit http://www.simbionix.com

    Contact:

    Inbal Mazor
    VP Marketing
    Simbionix
    mailto:inbal@simbionix.com
    Tel: +972-8-9211177 ext. 222
   http://www.simbionix.com


'/>"/>
SOURCE Simbionix Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Announces FDA Filings for Paliperidone Palmitate and INVEGA(R)
2. Johnson & Johnson to Provide Webcast Presentation of Tapentadol Phase 3 Clinical Data Presented at American Pain Societys Annual Meeting
3. Prometheus and Rosetta Genomics Announce License and Collaboration Agreement
4. Premier Research Announces Milestone Investigational New Drug Application
5. PEAK Surgical Announces Completion of First PRECISE Clinical Study, Receipt of Medical Design Excellence Award for PEAK(R) Surgery System and Achievement of Over 1,000 Surgeries Using PEAK PlasmaBlade(TM)
6. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
7. Cephalon Announces Positive Results from a Phase Three Study of NUVIGIL in Jet Lag Disorder
8. Cynosure Announces Presentation of Favorable Results from Post-Marketing Studies of Smartlipo MPX
9. Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis
10. Schering-Plough Announces Results of the Early ACS Trial
11. Hyperion Therapeutics Announces Results for Phase II Study in Urea Cycle Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... PALMA, Spain , January 23, ... a clinical-stage biopharmaceutical company focused on treatments for ... has been enrolled in the Phase IIb "CaLIPSO ... the treatment of cardiovascular calcification (CVC) in end-stage-renal-disease ... ESRD patients, in the last stage of chronic ...
(Date:1/21/2017)... , Jan 20, 2017 Research ... Clinical Laboratory Testing Market By Type of Test (Tumor, Clinical ... & By Type of Diseases (Tuberculosis, Influenza, Cancer, HIV/AIDS etc.), ... ... attractive destination for healthcare services, market segments, especially clinical lab ...
(Date:1/21/2017)... -- Research and Markets has announced the addition of ... Route Of Administration, End User - Forecast to 2025" report ... ... a CAGR of around 7.8% over the next decade to reach ... analyzes the global markets for Advanced Drug Delivery across all the ...
Breaking Medicine Technology:
(Date:1/23/2017)... Switzerland (PRWEB) , ... January 23, 2017 , ... ... lab and production applications. However, choosing the right method is paramount to success. ... occur more often in situations where multiple persons use the same equipment. Rare ...
(Date:1/23/2017)... ... 2017 , ... Old School Labs™, makers of the wildly popular all-natural sports ... Ansley to its growing team of brand ambassadors. The Olympia top finisher and former ... than a year was able to turn professional, participating in the 2013 NPC USA ...
(Date:1/23/2017)... ... ... at the Mill”: a story of love and redemption, hope and uncertainty as a ... , “The Inn at the Mill” is the creation of published author, Lois Kulp, ... now living in Berks County on Crow Hill. The inn, the mill and ...
(Date:1/23/2017)... ... ... “Life Under Blankets”: an entrancing story about one woman's travels through the wilderness ... of published author, Kimberly Mitchell, who earned her bachelor’s degree in English education at ... master’s degree in education in the field of curriculum and instruction. Kimberly’s passion for ...
(Date:1/22/2017)... FRANCE (PRWEB) , ... January 22, 2017 , ... Phytocéane ... Ocean, isolated from the rest of the world with ZANZIBAR MILKY CREAM. Inspired by ... used key ingredients like Virgin Coconut Oil and moisturizing vegetal coral to create this ...
Breaking Medicine News(10 mins):